MiMedx Group (MDXG) Stock Forecast & Price Target

MiMedx Group is viewed favorably because its core chronic wound care franchise rests on a decade-plus leadership position, strong peer-reviewed clinical data, and vertically integrated manufacturing and sales capabilities that should help it benefit as patients migrate back to traditional care settings. Despite a difficult CMS-related reimbursement backdrop that pushed 1Q26 net sales to $59.0 mln, Advanced Surgical still grew 13.2% y/y to $36.4 mln, and two revenue streams representing about $200 mln of sales were not impacted by the recent schedule updates. Management’s expected $40 mln of annual savings from restructuring, the $100 mln buyback authorization, and signs that 1Q26 should be the bottom support the view that margins and growth can recover as demand patterns normalize.

MiMedx Group is facing a negative fundamental backdrop because 1Q26 results were pressured by Medicare wound reimbursement changes that began January 1, lower pricing per cm2, and new pre-authorization processes in the six WISeR states, which together caused several large practices to stop ordering and one MAC to halt wound care submissions. As a result, quarterly sales came in about 10% light and annual guidance was cut by about 20% at the midpoint, while management’s CEO and four senior members taking salary reductions through December 31, 2026 signals cost pressure rather than operating momentum. The company also remains exposed to supply constraints in donor tissue, fierce competition in 361-regulated skin substitutes, and concentration risk because about 76% of 2024 revenue came from customers tied to its primary GPOs and IDNs.